Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-hodgkin lymphoma

Coyle, L., Morley, N.J. orcid.org/0000-0002-0497-975X, Rambaldi, A. et al. (6 more authors) (2018) Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-hodgkin lymphoma. In: Blood. 60th ASH Annual Meeting, 01-04 Dec 2018, San Diego, CA, USA. American Society of Hematology , p. 400.

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2018 by The American Society of Hematology. This is an author-produced version of a paper subsequently published in Blood. Uploaded in accordance with the publisher's self-archiving policy.
Dates:
  • Published (online): 21 November 2018
  • Published: 29 November 2018
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 23 May 2019 13:50
Last Modified: 21 Nov 2019 01:39
Published Version: http://www.bloodjournal.org/content/132/Suppl_1/40...
Status: Published
Publisher: American Society of Hematology
Refereed: Yes
Identification Number: https://doi.org/10.1182/blood-2018-99-112280
Related URLs:

Export

Statistics


CORE (COnnecting REpositories)